Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06WOF
|
|||
| Drug Name |
Rova-T
|
|||
| Synonyms |
rovalpituzumab tesirine; Rovalpituzumab Tesirine; Rova-t; Rovalpituzumab-Tesirin; UNII-P256HB60FF; Rovalpituzumab tesirine [INN]; P256HB60FF; Rovalpituzumab tesirine [WHO-DD]; Rovalpituzumab tesirine [USAN:INN]; SC0002; 1613313-09-9
Click to Show/Hide
|
|||
| Indication | Small-cell lung cancer [ICD-11: 2C25.Y; ICD-9: 162.9] | Phase 3 | [1], [2], [3] | |
| Neuroendocrine cancer [ICD-11: 2B72.1; ICD-9: 209] | Phase 1 | [2], [3] | ||
| Company |
StemcentRx South San Francisco, CA
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C78H108N10O25S
|
|||
| Canonical SMILES |
CC1=CN2C(C1)C=NC3=CC(=C(C=C3C2=O)OC)OCCCCCOC4=C(C=C5C(=C4)N(C(C6CC(=CN6C5=O)C)O)C(=O)OCC7=CC=C(C=C7)NC(=O)C(C)NC(=O)C(C(C)C)NC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCNC(=O)CCN8C(=O)CC(C8=O)SCC(C(=O)O)N)OC
|
|||
| InChI |
1S/C78H108N10O25S/c1-49(2)70(84-68(90)16-21-103-23-25-105-27-29-107-31-33-109-35-36-110-34-32-108-30-28-106-26-24-104-22-17-80-67(89)15-18-85-69(91)43-66(76(85)97)114-48-58(79)77(98)99)72(93)82-52(5)71(92)83-54-13-11-53(12-14-54)47-113-78(100)88-60-42-65(63(102-7)40-57(60)74(95)87-46-51(4)38-61(87)75(88)96)112-20-10-8-9-19-111-64-41-59-56(39-62(64)101-6)73(94)86-45-50(3)37-55(86)44-81-59/h11-14,39-42,44-46,49,52,55,58,61,66,70,75,96H,8-10,15-38,43,47-48,79H2,1-7H3,(H,80,89)(H,82,93)(H,83,92)(H,84,90)(H,98,99)/t52-,55-,58-,61-,66+,70-,75-/m0/s1
|
|||
| InChIKey |
NQUUPTGRJYIXSL-YPDXTJLXSA-N
|
|||
| CAS Number |
CAS 1613313-09-9
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Delta-like protein 3 (DLL3) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Endocrine resistance | |||
| Notch signaling pathway | ||||
| Th1 and Th2 cell differentiation | ||||
| Pathways in cancer | ||||
| Breast cancer | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.